The effects of ergoloid mesylates and ginkgo biloba on the pharmacokinetics of ticlopidine

Journal of Clinical Pharmacology

Volumn 46, Issue 6, 2006, Pages 628-634

  Lu, Wen Fen ^a   Huang, Jin Ding ^a   Lai, Ming Liang ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Ergoloid mesylates; Ginkgo biloba; Ticlopidine

Indexed keywords

CERENIN; DIHYDROERGOTOXINE MESILATE; ESTRONE SULFATE; GINKGO BILOBA EXTRACT; HODRIN; LICODIN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTING POLYPEPTIDE B; TICLOPIDINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INTESTINE ABSORPTION; MALE; NORMAL HUMAN;

ADULT; CELL LINE; DRUG INTERACTIONS; ERGOLOID MESYLATES; ESTRONE; FEMALE; GINKGO BILOBA; HUMANS; INTESTINAL ABSORPTION; MALE; ORGANIC ANION TRANSPORTERS; PLANT PREPARATIONS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 33745232469     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006287024     Document Type: Article

References (30)

1. Ito MK, Smith AR, Lee ML. Ticlopidine: a new platelet aggregation inhibitor. Clin Pharm. 1992;11:603-617.
2. McTavish D, Faulds D, Goa KL. Ticlopidine: an updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs. 1990;40:238-259.
3. Bertrand M, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) study. Circulation. 1998;98:1597-1603.
4. Balsano F, Coccheri S, Libretti A, et al. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J Lab Clin Med. 1989;114:84-91.
5. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1:1215-1220.
6. Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 1989;321:501-507.
7. Urban P, Macaya C, Rupprecht H, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation. 1998;98:2126-2132.
8. Hollister LE, Yesavage J. Ergoloid mesylates for senile dementias: unanswered questions. Ann Intern Med. 1984;100:894-898.
9. Wadworth AN, Chrisp P. Co-dergocrine mesylate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline. Drugs Aging. 1992;2:153-173.
10. Flynn BL, Ranno AE. Pharmacologic management of Alzheimer disease, II: antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999;33:188-197.
11. Schneider LS, Olin JT. Overview of clinical trials of hydergine in dementia. Arch Neurol. 1994;51:787-798.
12. DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets. 2000;1:25-58.
13. Gaby AR. Ginkgo biloba extract: a review. Alt Med Rev. 1996;1:236-242.
14. Tamai I, Nezu J, Uchino H, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000;273:251-260.
15. Kullak-Ublick GA, Ismair MG, Stieger B, et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001;120:525-533.
16. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003;306:703-708.
17. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002;71:11-20.
18. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther. 2004;76:167-177.
19. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2004;75:455-463.
20. Satoh H, Yamashita F, Tsujimoto M, et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005;33:518-523.
21. Dal Bo L, Verga F, Marzo A, Ambrosoli L, Poli A. Determination of ticlopidine in human plasma by high-performance liquid chromatography and ultraviolet absorbance detection. J Chromatogr B Biomed Appl. 1995;665:404-409.
22. Rona K, Ary K, Gachalyi B, Klebovich I. Liquid chromatographic method for the determination of ticlopidine in human plasma. J Chromatogr B Biomed Sci Appl. 1997;693:393-398.
23. Kusuhara H, Sugiyama Y. Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release. 2002;78:43-54.
24. Mizuno N, Sugiyama Y. Drug transporters: their role and importance in the selection and development of new drugs. Drug Metab Pharmacokinet. 2002;17:93-108.
25. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev. 2003;55:425-461.
26. Meijer DK, Hooiveld GJ, Schinkel AH, et al. Transport mechanisms for cationic drugs and proteins in kidney, liver and intestine: implication for drug interactions and cell-specific drug delivery. Nephrol Dial Transplant. 1999;14:1-3.
27. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther. 2005;78:260-277.
28. Kim RB. Transporters in drug disposition. Curr Opin Drug Discov Develop. 2000;3:94-101.
29. Russel FG, Masereeuw R, van Aubel RA. Molecular aspects of renal anionic drug transport. Annual Rev Physiol. 2002;64:563-594.
30. Schwarz UI, Gramatte T, Krappweis J, Oertel R, Kirch W. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther. 2000;38:161-167.